Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Danielle Fredman, Yulia Volchek, MD, Gabriel Heering, Keren Shichrur, PhD, Ronit Yerushalmi, MD, Noga Shem-Tov, MD, Elena Ribakovsky, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, MD, Jonathan Canaani, MD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134771

Published: 2020

Journal Articles

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Guy Bitansky, Elena Vasilev, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD, Meirav Kedmi, MD

Blood (2019) 134 (Supplement_1): 1534.

https://doi.org/10.1182/blood-2019-125218

Published: 2019

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Ohad Benjamini, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Meirav Kedmi, MD, Adrian Duek, MD, Drorit Merkel, MD, Merav Leiba, MD, Ivetta Danylesko, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, Yulia Volchek, MD

Blood (2016) 128 (22): 5429.

https://doi.org/10.1182/blood.V128.22.5429.5429

Published: 2016

Journal Articles

Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort

Eldar Priel, MD, Meirav Kedmi, MD, Tima Davidson, MD, Ginette Schiby, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD

Blood (2015) 126 (23): 5025.

https://doi.org/10.1182/blood.V126.23.5025.5025

Published: 2015

Journal Articles

Infections Associated with Bendamustine – a Retrospective Multicenter Study

Anat Gafter-Gvili, MD, Elena Ribakovsky, MD, Nadav Mizrahi, Abraham Avigdor, MD, Ariel Aviv, MD, Liat Vidal, MDMSc, Ron Ram, MD, Arnon Nagler, MD, Pia Raanani, MD, Ronit Gurion, MD

Blood (2014) 124 (21): 3077.

https://doi.org/10.1182/blood.V124.21.3077.3077

Published: 2014

Journal Articles

Essential Thrombocythemia Patients with CALR Mutations Have Increased Platelet Activation Markers Compared to JAK2V617F Mutated Patients

Maya Koren-Michowitz, MD, Hagit Hauschner, PhD, Yulia Shuly, MA, Meital Nagar, PhD, Elena Ribakovsky, MD, Mudi Misgav, MD, Odit Gutwein, MD, Uri Seligsohn, MD, Nurit Rosenberg, PhD, Arnon Nagler, MD

Blood (2014) 124 (21): 3223.

https://doi.org/10.1182/blood.V124.21.3223.3223

Published: 2014

Journal Articles

Transformation to Myelofibrosis and Blastic Transformation of PV Are Associated with Higher JAK2 Mutation Levels.

Maya Koren-Michowitz, MD, Ninette Amariglio, PhD, Joseph Landman, BA, Gideon Rechavi, MD, PhD, Elena Ribakovsky, MD, Yoram Cohen, MD, Arnon Nagler, MD, MSc

Blood (2007) 110 (11): 1555.

https://doi.org/10.1182/blood.V110.11.1555.1555

Published: 2007

Journal Articles

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 1650.

https://doi.org/10.1182/blood.V110.11.1650.1650

Published: 2007

Journal Articles

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Avichai Shimoni, MD, Izhar Hardan, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 1668.

https://doi.org/10.1182/blood.V110.11.1668.1668

Published: 2007

Journal Articles

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Avichai Shimoni, MD, Noga Shem-Tov, MD, Avital Rand, RN, Elena Ribakovsky, MD, Ronit Yerushalmi, MD, Izhar Hardan, MD, Arnon Nagler, MD

Blood (2007) 110 (11): 2998.

https://doi.org/10.1182/blood.V110.11.2998.2998

Published: 2007

NARROW

Evaluating Outcomes of Adult Patients with Acute Lymphoblastic Leukemia Treated on the GMALL Protocol

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort

Infections Associated with Bendamustine – a Retrospective Multicenter Study

Essential Thrombocythemia Patients with CALR Mutations Have Increased Platelet Activation Markers Compared to JAK2V617F Mutated Patients

Transformation to Myelofibrosis and Blastic Transformation of PV Are Associated with Higher JAK2 Mutation Levels.

Relapse of Acute Myeloid Leukemia after Allogeneic Stem-Cell Transplantation (SCT) with Myeloablative Conditioning Is Associated with Longer Survival Than Relapse after Reduced-Intensity Conditioning (RIC).

Reduced-Intensity Conditioning Is Associated with Shorter Duration of Chronic GVHD Than Myeloablative Conditioning and Provides Very Good Quality of Life for Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Treatment of Donor Graft Failure with Autologous or Allogenenic Stem-Cell Boost or a Second Allogeneic Transplant Based on Chimerism Testing.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only